- Home
- KG vs GALT Comparison
KG vs GALT Comparison
Compare KG & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KG
- GALT
- Stock Information
- Founded
- KG N/A
- GALT 2000
- Country
- KG Bermuda
- GALT United States
- Employees
- KG N/A
- GALT N/A
- Industry
- KG Property-Casualty Insurers
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- KG Finance
- GALT Health Care
- Exchange
- KG Nasdaq
- GALT Nasdaq
- Market Cap
- KG 266.5M
- GALT 232.3M
- IPO Year
- KG N/A
- GALT N/A
- Fundamental
- Price
- KG $27.78
- GALT $4.10
- Analyst Decision
- KG
- GALT Strong Buy
- Analyst Count
- KG 0
- GALT 3
- Target Price
- KG N/A
- GALT $6.00
- AVG Volume (30 Days)
- KG 21.4K
- GALT 279.0K
- Earning Date
- KG 08-15-2025
- GALT 08-14-2025
- Dividend Yield
- KG N/A
- GALT N/A
- EPS Growth
- KG N/A
- GALT N/A
- EPS
- KG N/A
- GALT N/A
- Revenue
- KG $5,462,137.00
- GALT N/A
- Revenue This Year
- KG N/A
- GALT N/A
- Revenue Next Year
- KG N/A
- GALT N/A
- P/E Ratio
- KG $646.28
- GALT N/A
- Revenue Growth
- KG 250.18
- GALT N/A
- 52 Week Low
- KG $20.51
- GALT $0.73
- 52 Week High
- KG $36.80
- GALT $4.41
- Technical
- Relative Strength Index (RSI)
- KG 55.63
- GALT 66.50
- Support Level
- KG $25.40
- GALT $3.50
- Resistance Level
- KG $27.72
- GALT $4.20
- Average True Range (ATR)
- KG 2.38
- GALT 0.31
- MACD
- KG -0.20
- GALT -0.03
- Stochastic Oscillator
- KG 57.82
- GALT 65.93
About KG Kestrel Group Ltd.
Kestrel Group Ltd is specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.